Comparison of LDL Cholesterol Concentrations by Friedewald Calculation and Direct Measurement in Relation to Cardiovascular Events in 27 331 Women
Authors:
Open Access
- 1 May 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (5) , 888-894
Abstract
Background: National Cholesterol Education Program (NCEP) guidelines recommend development of direct assays for LDL cholesterol (LDL-C) measurement, but it is unclear how these assays compare with Friedewald calculation in predicting cardiovascular disease (CVD). Methods: In a study of 27 331 healthy women with triglycerides ≤4.52 mmol/L (≤400 mg/dL), baseline fasting Friedewald LDL-C was compared with fasting and nonfasting direct homogenous measurement for incident CVD during an 11-year period. Results: Fasting LDL-C measurements obtained by the 2 methods were highly correlated (r = 0.976, P < 0.001). Compared with fasting Friedewald LDL-C, mean fasting direct LDL-C was 0.15 mmol/L (5.6 mg/dL) lower and nonfasting direct LDL-C 0.30 mmol/L (11.5 mg/dL) lower, both P < 0.0001. The adjusted hazard ratio per 1-SD increment was 1.23 [95% CI 1.15–1.32; 1-SD 0.88 mmol/L (34.1 mg/dL)] for fasting direct LDL-C and 1.22 [95% CI 1.14–1.30; 1-SD 0.90 mmol/L (34.9 mg/dL)] for fasting Friedewald. Nonfasting LDL-C was not associated with CVD by either method. Fasting LDL-C measurements fell into the same NCEP risk category with either method for 79.3% of participants, whereas they differed by 1 NCEP category for 20.7% of participants, with most classified into a lower-risk category by direct LDL-C. Conclusions: The association of LDL-C with CVD by the 2 methods was nearly identical in fasting samples. However, the lower direct LDL-C concentrations may misclassify many individuals into a lower NCEP category. Moreover, the lack of association of nonfasting direct LDL-C with CVD raises questions regarding the clinical utility of a direct assay for LDL-C in nonfasting blood samples.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (HL-43851)
- National Heart, Lung, and Blood Institute (CA-47988)
- National Cancer Institute
- Donald W. Reynolds Foundation
- Doris Duke Charitable Foundation
- AstraZeneca
- Novartis
- Merck
- American Heart Association (0670007N)
- National Heart, Lung, and Blood Institute (K08 HL094375)
This publication has 16 references indexed in Scilit:
- Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular EventsCirculation, 2008
- A brief history of lipid and lipoprotein measurements and their contribution to clinical chemistryClinica Chimica Acta, 2006
- Vitamin E in the Primary Prevention of Cardiovascular Disease and CancerJAMA, 2005
- Low-Dose Aspirin in the Primary Prevention of CancerJAMA, 2005
- A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in WomenNew England Journal of Medicine, 2005
- How should low-density lipoprotein cholesterol concentration be determined?2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Performance of Four Homogeneous Direct Methods for LDL-CholesterolClinical Chemistry, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Analytical performance and clinical efficacy of three routine procedures for LDL cholesterol measurement compared with the ultracentrifugation–dextran sulfate–Mg2+ methodClinica Chimica Acta, 2000